...
首页> 外文期刊>Clinical Pediatric Endocrinology >A pediatric case of insulinoma and a novel MEN1 mutation: the efficacy of the combination therapy of diazoxide and cornstarch
【24h】

A pediatric case of insulinoma and a novel MEN1 mutation: the efficacy of the combination therapy of diazoxide and cornstarch

机译:小儿胰岛素瘤病例和新型 MEN1 突变:二氮嗪和玉米淀粉联合治疗的疗效

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Introduction Insulinoma is a neuroendocrine tumor derived from the insulin-secreting pancreatic beta cells. In most adult patients with insulinoma, the combination of diazoxide and complex carbohydrates is effective for preventing hypoglycemia ( 1 ). However, in pediatric patients, the efficacy of the combination of diazoxide and complex carbohydrates remains unknown. Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder due to a loss-of-function mutation in the MEN1 gene, such as a frameshift mutation ( 2 ), and is characterized by the development of primary hyperparathyroidism, pancreatic endocrine tumors such as insulinoma, and pituitary tumors. Herein, we describe a pediatric patient with insulinoma and a novel MEN1 mutation, for whom the combination of diazoxide and cornstarch was effective in preventing hypoglycemia. Case Report The proband was a 14-yr-old Japanese girl. Her past medical history was unremarkable. Her paternal grandfather had insulinoma and nephrolithiasis, and her father had ureterolithiasis and gastrinoma. At 12 yr of age, she experienced afebrile convulsions due to hypoglycemia in the morning. We confirmed hyperinsulinemic hypoglycemia based on the results of a fasting test, which showed that her plasma glucose levels, insulin levels, and Fajans’ ratio were 33 mg/dL, 11.2 μIU/mL, and 0.34, respectively, after 7 h of fasting. We initiated diazoxide administration, 5 mg/kg/d in 3 divided doses, but her preprandial plasma glucose levels in the morning remained 50–60 mg/dL. We could not increase the dosage of diazoxide because of adverse effects including headaches and hirsutism. We introduced cornstarch in her regimen (60 g each in the morning and at bedtime). Her preprandial plasma glucose levels in the morning increased to above 65 mg/dL. Adverse effects of cornstarch were not apparent, except for weight gain. Subsequently, a pancreatic tumor, 1.0 cm in diameter, was detected using abdominal magnetic resonance imaging. At 13 yr of age, we resected the tumor surgically, and confirmed insulinoma pathologically. She had normoglycemia without diazoxide and cornstarch. She also had hypercalcemia (10.3–11.0 mg/dL, reference 8.5–10.2) and elevated intact parathyroid hormone levels (95–149 pg/mL, reference 10–65). Neck ultrasonography showed parathyroid enlargement, suggesting primary hyperparathyroidism. MEN1 was diagnosed clinically based on the presence of insulinoma and primary hyperparathyroidism. Pituitary magnetic resonance imaging showed no abnormalities. Mutation Analysis After receiving approval from the institutional review board in Keio University School of Medicine (institutional review board number 20140289) and obtaining informed consent from her parents, we extracted genomic DNA from peripheral blood samples of the proband using a standard protocol. We amplified all the coding exons and the flanking introns of the exons in the MEN1 gene and performed direct sequencing in both directions using an autosequencer. The sequencing identified a heterozygous frameshift variant, c.1679delG, p.Gly560Alafs*2 in the MEN1 gene ( Fig. 1 Fig. 1. Partial sequence of exon 10 of the MEN1 gene. The upper panel shows a chromatogram of the proband who has a heterozygous mutation, c.1679delG, p.Gly560Alafs*2, which is denoted by an arrow. The lower panel shows a chromatogram of the wild-type sequence. ). This variant was not found in the Universal mutation database-MEN1 mutations database, the Exome Aggregation Consortium database, or the Human Genetic Variation Database. Her father also harbored the same variant. Discussion We reported a pediatric case of MEN1 with a novel mutation in the MEN1 gene. Our patient could not maintain normoglycemia until receiving both diazoxide and cornstarch. The function of the MEN1 mutant protein of the proband is probably impaired because Gly560 is located in one of the nuclear localization signal regions, which are essential domains for DNA binding ( 3 ). Clinical manifestations of MEN1 seemed unrelated to the defect of the nuclear localization signal and differed between the proband and her father. In a previous report, a patient with the mutation c.1683delG, p.Met561Ilefs*27 had a lung carcinoid tumor and pituitary macroadenoma ( 4 ). Cornstarch is effective and safe to prevent hypoglycemia in pediatric patients with congenital hyperinsulinemic hypoglycemia or glycogen storage disease type 1. The combination of diazoxide and cornstarch was effective and safe to prevent hypoglycemia in our patient, as shown in a previous report of a single pediatric case of MEN1-associated insulinoma ( 5 ). These data indicate that adding cornstarch to diazoxide can be a useful treatment choice for pediatric MEN1-associated insulinoma when the maximum dosage of diazoxide is insufficient or when the dosage of diazoxide cannot be increased because of adverse effects. Conflict of Interest All authors have no financial relationships relevant to this article
机译:简介胰岛素瘤是一种神经内分泌肿瘤,起源于分泌胰岛素的胰岛β细胞。在大多数成年胰岛素瘤患者中,二氮嗪和复合碳水化合物的组合可有效预防低血糖症(1)。然而,在儿科患者中,二氮嗪和复合碳水化合物的组合的功效仍然未知。多发性内分泌肿瘤1型(MEN1)是由于MEN1基因的功能缺失突变(如移码突变)引起的常染色体显性遗传疾病,其特征是原发性甲状旁腺功能亢进症,胰腺内分泌肿瘤等。如胰岛素瘤和垂体瘤。本文中,我们描述了患有胰岛素瘤和新型MEN1突变的小儿科患者,二氮嗪和玉米淀粉的组合可有效预防低血糖症。病例报告该先证者是一名14岁的日本女孩。她过去的病史并不明显。她的祖父患有胰岛素瘤和肾结石症,父亲患有输尿管结石症和胃泌素瘤。在12岁时,她早晨因血糖过低而出现高热惊厥。我们根据禁食测试的结果证实了高胰岛素血症性低血糖,这表明禁食7小时后她的血浆葡萄糖水平,胰岛素水平和Fajans比分别为33 mg / dL,11.2μIU/ mL和0.34。我们开始以3次分装5毫克/千克/天的剂量重氮嗪给药,但她早晨的餐前血浆葡萄糖水平仍为50-60毫克/分升。由于包括头痛和多毛症在内的不良反应,我们无法增加二氮嗪的剂量。我们在她的治疗方案中加入了玉米淀粉(早上和睡前各60克)。早晨她的餐前血浆葡萄糖水平增加到65 mg / dL以上。除体重增加外,玉米淀粉的不良影响不明显。随后,使用腹部磁共振成像检测到直径为1.0 cm的胰腺肿瘤。在13岁时,我们通过手术切除了肿瘤,并在病理学上证实了胰岛素瘤。她的血糖正常,没有二氮嗪和玉米淀粉。她还患有高钙血症(10.3-11.0 mg / dL,参考8.5-10.2)和完整的甲状旁腺激素水平升高(95-149 pg / mL,参考10-65)。颈部超声检查显示甲状旁腺肿大,提示原发性甲状旁腺功能亢进。 MEN1是根据胰岛素瘤和原发性甲状旁腺功能亢进症的存在进行临床诊断的。垂体磁共振成像未见异常。突变分析在获得庆应义School大学医学院的机构审查委员会的批准(机构审查委员会编号20140289)并获得其父母的知情同意后,我们使用标准方案从先证者的外周血样本中提取了基因组DNA。我们扩增了MEN1基因中所有编码外显子和外显子的侧翼内含子,并使用自动测序仪在两个方向上进行了直接测序。测序鉴定出MEN1基因中杂合的移码变体c.1679delG,p.Gly560Alafs * 2(图1图1. MEN1基因外显子10的部分序列。上图显示了具有以下特征的先证者的色谱图)杂合突变,c.1679delG,p.Gly560Alafs * 2,用箭头表示。下图显示了野生型序列的色谱图。在通用突变数据库-MEN1突变数据库,外显子组聚合协会数据库或人类遗传变异数据库中找不到此变异。她的父亲也怀有同样的想法。讨论我们报道了MEN1患儿,其中MEN1基因发生了新的突变。我们的患者在同时服用二氮嗪和玉米淀粉之前无法维持血糖正常。先证者的MEN1突变蛋白的功能可能受到损害,因为Gly560位于一个核定位信号区域之一,该区域是DNA结合的必需域(3)。 MEN1的临床表现似乎与核定位信号的缺陷无关,并且先证者和父亲之间也有所不同。在先前的报道中,突变为c.1683delG,p.Met561Ilefs * 27的患者患有肺类癌和垂体大腺瘤(4)。先天性高胰岛素低血糖或糖原贮积病类型1的小儿,玉米淀粉可有效安全地预防低血糖症,如先前单个儿童病例的报告所示,二氮嗪和玉米淀粉的组合可有效且安全地预防本例患者的低血糖症。与MEN1相关的胰岛素瘤(5)。这些数据表明,当二氮嗪的最大剂量不足或由于不良反应而不能增加二氮嗪的剂量时,在二氮嗪中添加玉米淀粉可能是儿童MEN1相关性胰岛素瘤的有用治疗选择。利益冲突所有作者都没有与本文相关的财务关系

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号